In Vivo CAR-T And Gene Editing: The Manufacturing Reality Behind The Promise

In vivo CAR-T has advanced rapidly, and the manufacturing challenges behind these therapies have evolved just as quickly. Both lipid nanoparticles (LNPs) and viral vectors have emerged as leading delivery platforms, yet each brings a distinct set of technical, analytical, and scalability constraints that are already influencing which programs progress successfully and which struggle to move forward. In this on-demand webinar, experts explored the practical manufacturing realities that often receive less attention than the scientific breakthroughs themselves.

• What does it truly take to manufacture a targeted RNA-LNP capable of selectively reprogramming T cells in vivo? How do viral vector programs perform when process complexity, analytical requirements, and scale-up pressures intensify?
• And what happens when assumptions made during early development encounter the realities of commercial manufacturing?

During the session, experts from Lonza examined real-world case studies across both viral and non-viral platforms, highlighting how specific manufacturing and process challenges were identified, addressed, and resolved. The discussion provided insight into the critical decisions that shape manufacturability from the earliest stages of development and demonstrated why manufacturing readiness must be considered long before clinical scale is reached.

Viewers will gain a deeper understanding of how different delivery platforms face many of the same manufacturing pressures despite their unique advantages and limitations, as the session outlines how viral vector programs require robust analytics, tight process control, and scalable manufacturing strategies, while targeted LNP approaches introduce their own layers of formulation and characterization complexity that the field is still actively working to optimize. Drawing on hands-on experience across both modalities, watch as Lonza’s team shares practical lessons learned and discusses what developers should consider when building more scalable, resilient in vivo therapeutic programs for the future.